for effective life science R&D and partnering
Associates is a Boston-based consulting firm, founded in 1993, that specializes
in science and technology strategy for life science companies.
assist your company to achieve its business goals in new product development and
commercialization. Our focus is on effective R&D, business development, and
Clients have used our consulting services to
- discover and develop new drugs, diagnostics,
and research products
- improve their drug pipelines
and evaluate potential partners
- develop new applications for their technologies
- penetrate new markets
information about how we can assist your company, please see "About
Haberman Associates". Or use our site map
to navigate our entire site.
For an initial discussion
of your company's needs, or if you have any questions about our firm, please contact
Haberman Associates is a member of the Boston-based
Biopharmaceutical Consortium and an Affiliate of the North
Carolina-based consulting consortium Innovalyst.
Working with our consortium partners, we can form project teams of senior consultants
to handle both small and large consulting engagements, for companies of all sizes
November 8, 2010: Dr. Haberman quoted
in article on the Bristol-Myers Squibb acquisition of ZymoGenetics in Nature Biotechnology.
See our News Page
4, 2010: RNAi Therapeutics: Second Generation Candidates Build Momentum
published by Cambridge Healthtech Institute. See our News
June 4, 2010: The Biopharmconsortium
Blog has moved to our own site. See our News
March 16, 2010: Reducing Attrition
In Silico published in Bio-IT World. See our News
March 5, 2010: Animal Models for
Therapeutic Strategies published by Cambridge Healthtech Institute. See
our News Page.
Phase II Attrition Problem"
(Published in the August 2009 issue of
Genetic Engineering News.)
to Overcome Blood-Brain Barrier"
(Published in the February 1, 2009
issue of Genetic Engineering News.)
Unmet Type 2 Diabetes Needs"
(Published in the January 1, 2008 issue
of Genetic Engineering News.)
Clinical Developments in Type 2 Diabetes: Preventing Diabetes and Preventing Cardiovascular
Events in Diabetics"
(Published in the October 19, 2006 issue of
CHI's Pharma DD.)
Issues Hamper Dual PPAR Agonists: Is Partial Antagonism the Solution?"
(Published in the September 22, 2006 issue of CHI's Pharma DD.)
the Obesity Barrier: Near-Term Prospects for Breakthrough Treatments"
(Published in the December 22, 2005 issue of CHI's PharmaWeek.)
to Move Beyond Target Validation: Targets and Druggability for Small
Large Molecule Drugs"
(Published in the December 1, 2005 issue of
Genetic Engineering News.)
Strategies in Animal Models: the Case of Alzheimer's Disease."
in the September 15, 2004 issue of Genetic Engineering News.)